Weinfurt KP - Search Results

1

A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors.

Schulman KA, Seils DM, Timbie JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM. Schulman KA, et al. Among authors: weinfurt kp. N Engl J Med. 2002 Oct 24;347(17):1335-41. doi: 10.1056/NEJMsa020349. N Engl J Med. 2002. PMID: 12397192

2

Measuring agreement between patient and proxy responses to multidimensional health-related quality-of-life measures in clinical trials. An application of psychometric profile analysis.

Weinfurt KP, Trucco SM, Willke RJ, Schulman KA. Weinfurt KP, et al. J Clin Epidemiol. 2002 Jun;55(6):608-18. doi: 10.1016/s0895-4356(02)00392-x. J Clin Epidemiol. 2002. PMID: 12063103

3

Practitioner acceptance of the dofetilide risk-management program.

LaPointe NM, Kramer JM, Weinfurt KP, Califf RM. LaPointe NM, et al. Among authors: weinfurt kp. Pharmacotherapy. 2002 Aug;22(8):1041-6. doi: 10.1592/phco.22.12.1041.33611. Pharmacotherapy. 2002. PMID: 12173789

4

The correlation between patient characteristics and expectations of benefit from Phase I clinical trials.

Weinfurt KP, Castel LD, Li Y, Sulmasy DP, Balshem AM, Benson AB 3rd, Burnett CB, Gaskin DJ, Marshall JL, Slater EF, Schulman KA, Meropol NJ. Weinfurt KP, et al. Cancer. 2003 Jul 1;98(1):166-75. doi: 10.1002/cncr.11483. Cancer. 2003. PMID: 12833469

5

Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception.

Weinfurt KP, Sulmasy DP, Schulman KA, Meropol NJ. Weinfurt KP, et al. Theor Med Bioeth. 2003;24(4):329-44. doi: 10.1023/a:1026072409595. Theor Med Bioeth. 2003. PMID: 14620488

6

Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials.

Weinfurt KP, Depuy V, Castel LD, Sulmasy DP, Schulman KA, Meropol NJ. Weinfurt KP, et al. Cancer. 2005 Jan 1;103(1):140-7. doi: 10.1002/cncr.20730. Cancer. 2005. PMID: 15534885

7

Policies of academic medical centers for disclosing financial conflicts of interest to potential research participants.

Weinfurt KP, Dinan MA, Allsbrook JS, Friedman JY, Hall MA, Schulman KA, Sugarman J. Weinfurt KP, et al. Acad Med. 2006 Feb;81(2):113-8. doi: 10.1097/00001888-200602000-00003. Acad Med. 2006. PMID: 16436571 Free PMC article.

8

Views of potential research participants on financial conflicts of interest: barriers and opportunities for effective disclosure.

Weinfurt KP, Friedman JY, Allsbrook JS, Dinan MA, Hall MA, Sugarman J. Weinfurt KP, et al. J Gen Intern Med. 2006 Sep;21(9):901-6. doi: 10.1111/j.1525-1497.2006.00502.x. J Gen Intern Med. 2006. PMID: 16918732 Free PMC article.

9

Disclosing conflicts of interest in clinical research: views of institutional review boards, conflict of interest committees, and investigators.

Weinfurt KP, Friedman JY, Dinan MA, Allsbrook JS, Hall MA, Dhillon JK, Sugarman J. Weinfurt KP, et al. J Law Med Ethics. 2006 Fall;34(3):581-91, 481. doi: 10.1111/j.1748-720x.2006.00072.x. J Law Med Ethics. 2006. PMID: 17144182 Free PMC article.

10

Developing model language for disclosing financial interests to potential clinical research participants.

Weinfurt KP, Allsbrook JS, Friedman JY, Dinan MA, Hall MA, Schulman KA, Sugarman J. Weinfurt KP, et al. IRB. 2007 Jan-Feb;29(1):1-5. IRB. 2007. PMID: 17364012 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results